Results 41 to 50 of about 7,946,940 (284)

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies [PDF]

open access: yes, 2012
BACKGROUND: Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades.
Thomas, GN   +492 more
core   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Correlation Between Different Salivary Interleukins and Clinical Periodontal Parameters

open access: yesMedical Journal of Babylon
Background: Periodontitis is a multifactorial disease that affects tooth-supporting structures which consequently lead to loss of tooth support and tooth loss. Interleukins showed an important role in periodontal destruction.
Sura Dakhil Jassim   +2 more
doaj   +1 more source

Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. [PDF]

open access: yes, 2014
Interleukin-12 is a pro-inflammatory cytokine which promotes Th1 and cytotoxic T lymphocyte activities, such as Interferon-[Formula: see text] secretion. For this reason Interleukin-12 could be a powerful therapeutic agent for cancer treatment.
Kang-Ling Liao, Xue-Feng Bai, and Avner Friedman   +9 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

"Recurrent Non-Typhoidal Salmonella Bacteremia in a Patient with Interleukin -12p40 Deficiency "

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2004
The South eastern region of Iran is an endemic area for salmonellosis. Sometimes bacteremia due to nontyphoidal salmonella occurs but certain patients are at increased risk for recurrent bacteremia.
Batool Sharifi Mood   +11 more
doaj  

Association Between Interleukin-12 and Sarcopenia

open access: yesJournal of Inflammation Research, 2021
Yuan-Yuei Chen,1– 3 Tung-Wei Kao,3 Yi-Lin Chiu,4 Tao-Chun Peng,3 Hui-Fang Yang,3 Wei-Liang Chen3,4 1Department of Pathology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China ...
Chen YY   +5 more
doaj  

Accelerated wound healing phenotype in Interleukin 12/23 deficient mice

open access: yesJournal of Inflammation, 2011
Background The concept that a strong inflammatory response involving the full complement of cytokines and other mediators is critical for unimpaired healing has been challenged by wound healing studies using transgenic and knockout (KO) mice. The present
Matias Marie AT   +4 more
doaj   +1 more source

Interleukin-12: A master regulator [PDF]

open access: yesThe Journal of Experimental Medicine, 2007
Early resistance to pathogens requires a swift response from NK cells. In 1989, Giorgio Trinchieri identified an NK growth factor and activator, later called interleukin-12 (IL-12). This discovery helped reveal the regulatory link between innate and adaptive immunity.
openaire   +2 more sources

Home - About - Disclaimer - Privacy